ReviewCurrent pharmaceutical design2010
Structure-based vaccine design in HIV: blind men and the elephant?
Review in Current pharmaceutical design, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer.Nature communications · 2022Article
- Flow Virometry Quantification of Host Proteins on the Surface of HIV-1 Pseudovirus Particles.Viruses · 2020Article
- Review
- Structural Vaccinology for Viral Vaccine Design.Frontiers in microbiology · 2019Review
- MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an EnterotoxigenicJournal of vaccines & vaccination · 2017Article
- Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design.Frontiers in immunology · 2017Article
- Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory.International journal of molecular sciences · 2016Review
- N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03.Journal of acquired immune deficiency syndromes (1999) · 2015Article
- A single amino acid deletion in the matrix protein of porcine reproductive and respiratory syndrome virus confers resistance to a polyclonal swine antibody with broadly neutralizing activity.Journal of virology · 2015Article
- Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones.Journal of translational medicine · 2014Article
- The stem of vesicular stomatitis virus G can be replaced with the HIV-1 Env membrane-proximal external region without loss of G function or membrane-proximal external region antigenic properties.AIDS research and human retroviruses · 2014Article
- Article
- An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.Frontiers in immunology · 2014Review
- Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1.Current HIV research · 2013Article
- Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.Journal of virology · 2013Article
- Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.Journal of virology · 2013Article
- Neutralizing antibodies to HIV-1 induced by immunization.The Journal of experimental medicine · 2013Review
- A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization.Retrovirology · 2013Article
- Designing a soluble near full-length HIV-1 gp41 trimer.The Journal of biological chemistry · 2013Article
- The molecular basis of HIV entry.Cellular microbiology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Traditional vaccine approaches have failed for HIV and novel strategies are now being sought to develop immunogens designed to elicit specific activity against known broad neutralization epitopes. Structure-based vaccine design has great potential but, thus far, remains a largely unproven concept. Further structural information for the envelope (Env) glycoproteins, gp120 and gp41, is needed, particularly for understanding trimer-specific antibodies and their epitopes and to clarify atomic details of the structural elements responsible for masking crucial epitopes and for mediating the conformational rearrangements undertaken during the process of receptor-binding and membrane fusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.